The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMainz Biomed N.V. (NASDAQ:MYNZ) has successfully raised $2.15 million in gross proceeds through an at-the-market (ATM) equity offering. The biotechnology company sold 1,735,194 ordinary shares on the Nasdaq Capital Market. This capital raise took place between January 5 and January 23. The offering is part of a broader ATM program, established in October 2025, which authorizes the company to sell up to $10 million in ordinary shares. While providing crucial funding, the offering also involves share dilution for existing shareholders. This strategic move aims to strengthen the company's financial position and support its future operations.